5 terminated. 5 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Terminated 5 |
| Phase 2 | 3 | Terminated 3 |
Follow Neurofibromatoses: new trials by email Literature Review of Neurofibromatoses trials Research Report on Neurofibromatoses
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas REC-2282, Placebo - Neurofibromatosis Type 2 | Phase 2 / Phase 3 | Terminated | Recursion Pharmaceuticals Inc. | 25 | 2022-06-20 | 2026-08-17 |
| A Long-term Study of NPC-12G Gel in Neurofibromatosis Type I NPC-12G gel - Neurofibromatosis | Phase 3 | Terminated | Nobelpharma | 100 | 2020-07-08 | 2022-05-24 |
| Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections Brolucizumab, Aflibercept - Age-Related Macular Degeneration | Phase 3 | Terminated | Novartis Pharmaceuticals | 535 | 2018-10-30 | 2023-01-30 |
| Effect of Lamotrigine on Cognition in NF1 Lamotrigine, Placebo - Neurofibromatosis Type 1 | Phase 2 / Phase 3 | Terminated | Erasmus Medical Center | 41 | 2014-10-01 | 2020-04-14 |
| Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors imatinib mesylate - Malignant Peripheral Nerve Sheath Tumors | Phase 2 / Phase 3 | Terminated | Novartis Pharmaceuticals | 11 | 2006-05-01 | 2012-08-07 |
Neurofibromatosis 2 (2) · Macular Degeneration (1) · Nerve Sheath Neoplasms (1) · Neurofibromatosis 1 (1) · Neurofibrosarcoma (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (5) · Genetic Diseases, Inborn (5) · Heredodegenerative Disorders, Nervous System (5) · Neoplasms (5) · Neoplasms by Histologic Type (5) · Neoplasms, Nerve Tissue (5) · Neoplastic Syndromes, Hereditary (5) · Nervous System Diseases (5) · Neurocutaneous Syndromes (5) · Neurodegenerative Diseases (5) · Neurofibroma (5) · Nerve Sheath Neoplasms (4) · Cranial Nerve Diseases (2) · Cranial Nerve Neoplasms (2)
HDAC-42 (1) · Imatinib Mesylate (1) · Lamotrigine (1) · aflibercept (1) · brolucizumab (1)
Novartis Pharmaceuticals (2) · Erasmus Medical Center (1) · Nobelpharma (1) · Recursion Pharmaceuticals Inc. (1)
United States (2) · Belgium (1) · Germany (1) · Japan (1) · Netherlands (1) · Puerto Rico (1) · Spain (1) · United Kingdom (1)
Henriette A Moll, MD, PhD (1) · Ype Elgersma, PhD (1)